Nucleai Adds $14 Million in a Financing Led by Merck’s VC Arm

Spatial AI biomarker startup Nucleai that maps cellular interactions within tissue samples to predict therapeutic outcomes has raised $14 million in financing, bringing the total funding of the company to $60 million. The financing was led by M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and supported by existing investors Section 32 (which was established by the former CEO of Google Ventures, Bill Maris), Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and leading Israeli VC firm Grove Ventures.

>> Click here to read the full article originally published in CTech: https://www.calcalistech.com/ctechnews/article/r11brac1a